EWTX - Edgewise Therapeutics, Inc. Stock Price, Fair Value and News

$23.32+0.34 (+1.48%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EWTX Price Action

Last 7 days

-8.6%

Last 30 days

29.8%

Last 90 days

59.5%

Trailing 12 Months

-27.0%

EWTX RSI Chart

EWTX Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

-15.7

Price/Sales (Trailing)

100.36

Price/Free Cashflow

-13.55

EWTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EWTX Fundamentals

EWTX Revenue

Revenue (TTM)

24.6M

Rev. Growth (Yr)

-1.76%

Rev. Growth (Qtr)

5.34%

EWTX Earnings

Earnings (TTM)

-157.2M

Earnings Growth (Yr)

-19.15%

Earnings Growth (Qtr)

-12.6%

EWTX Profitability

Return on Equity

-28.15%

Return on Assets

-26.95%

Free Cashflow Yield

-7.38%

EWTX Investor Care

Shares Dilution (1Y)

11.81%

EWTX Alerts

1 major insider buys and 1 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	24.6M	0
2024	17.6M	0	20.0M	22.1M
2023	6.7M	10.2M	13.1M	14.2M
2022	526.0K	843.0K	1.5M	4.0M
2021	48.0K	152.0K	278.0K	402.0K
2020	0	0	0	69.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

CEO	Dr. Kevin Koch Ph.D.
WEBSITE	edgewisetx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	74

Edgewise Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Edgewise Therapeutics, Inc.? What does EWTX stand for in stocks?

EWTX is the stock ticker symbol of Edgewise Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Edgewise Therapeutics, Inc. (EWTX)?

As of Wed Dec 03 2025, market cap of Edgewise Therapeutics, Inc. is 2.47 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EWTX stock?

You can check EWTX's fair value in chart for subscribers.

Is Edgewise Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether EWTX is over valued or under valued. Whether Edgewise Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Edgewise Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EWTX.

What is Edgewise Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, EWTX's PE ratio (Price to Earnings) is -15.7 and Price to Sales (PS) ratio is 100.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EWTX PE ratio will change depending on the future growth rate expectations of investors.